Joseph Treat, MD
Dr. Joseph Treat is a medical oncologist at the Fox Chase Cancer Center of Temple Health in Philadelphia, Pennsylvania. Since 1991, he has dedicated his practice and career to the exclusive care of patients who have been diagnosed with either lung cancer or malignant pleural mesothelioma.[1]
Dr. Treat values the multidisciplinary approach that is used at Fox Chase Cancer Center, where he and colleagues with expertise in surgery, radiation oncology, and pulmonology work together to provide the best possible outcomes for patients faced with challenging chest malignancies.
Education and Career
Dr. Treat earned his medical degree from the Lewis Katz School of Medicine at Temple University in Philadelphia, Pennsylvania, then went on to complete an internship and residency in Internal Medicine at Georgetown University Hospital in Washington DC. He remained at Georgetown to complete a fellowship in Medical Oncology at the hospital’s Lombardi Cancer Center.[1]
Research
Dr. Treat is involved with a wide range of studies in lung cancer, including many clinical trials involving new drugs. He is also a member of Fox Chase Cancer Center’s Cancer Signaling and Microenvironment research program, which studies signaling processes, their cancer cell-intrinsic adaptation, and how they are affected by extrinsic cell-to-cell communication and components of their microenvironment.[f
His recent works include:[1]
Clinical Trials
- Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC. Start of enrollment: 2019 Sep 04. RECRUITING, PHASE 2
Publications & Presentations
- Validation of a Molecular Diagnostic Test for Circulating Tumor DNA by Next-Gen Sequencing. Sandra V Fernandez, Yin Fei Tan, Shilpa Rao, Patricia Fittipaldi, Fathima Sheriff, Hossein Borghaei, Efrat Dotan, Jennifer S Winn, Martin J Edelman, Joseph Treat, Juli…>; International Journal of Molecular Sciences. 2023 Oct 30
- Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Har…. J Nicholas Bodor, Jyoti D Patel, Heather A Wakelee, Benjamin P Levy, Hossein Borghaei, Bruna Pellini, Michael R Costello, Jonathan E Dowell, Gene Finley, Chao H Huang,…>; Clinical Lung Cancer. 2023 Nov 1
- Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy. J Nicholas Bodor, Jessica R Bauman, Elizabeth A Handorf, Eric A Ross, Margie L Clapper, Joseph Treat>; Journal of Cancer Research and Clinical Oncology. 2023 May 1
